Vanillin

Vanillin

SCHEMBL356799

CCOCC.COc1cc(C=O)ccc1O

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.81
HPGD P15428 2/20 0.81
TDP1 Q9NUW8 2/20 0.81
TRIM24 O15164 1/20 0.81
ALDH5A1 P51649 1/20 0.81
ABAT P80404 1/20 0.81
TRIM33 Q9UPN9 1/20 0.81
AOX1 Q06278 1/20 0.60
XDH P47989 1/20 0.58
MAOB P27338 2/20 0.57
TSHR P16473 3/20 0.56
TRPA1 O75762 1/20 0.56
CYP2D6 P10635 3/20 0.55
CYP2C9 P11712 3/20 0.55
CYP1A2 P05177 3/20 0.55
KDM4E B2RXH2 3/20 0.55
MAPT P10636 3/20 0.55
NFE2L2 Q16236 3/20 0.55
HSD17B10 Q99714 2/20 0.55
TYR P14679 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Vanillin SCHEMBL4411107 0.97 ALDH1A1 (0.76) ALDH1A1HPGDTDP1TRIM24ALDH5A1
Vanillin SCHEMBL27673973 0.92 ALDH1A1 (0.89) ALDH1A1HPGDTDP1TRIM24ALDH5A1
Vanillin SCHEMBL14975994 0.92 ALDH1A1 (0.68) ALDH1A1HPGDTDP1TRIM24ALDH5A1
Vanillin SCHEMBL44060 0.90 ALDH1A1 (0.86) ALDH1A1HPGDTDP1TRIM24ALDH5A1
Vanillin SCHEMBL1213 0.90 ALDH1A1 (1.00) ALDH1A1HPGDTDP1TRIM24ALDH5A1
Vanillin SCHEMBL29354839 0.90 ALDH1A1 (1.00) ALDH1A1HPGDTDP1TRIM24ALDH5A1
Vanillin SCHEMBL720723 0.90 ALDH1A1 (1.00) ALDH1A1HPGDTDP1TRIM24ALDH5A1
Ethyl Vanillin SCHEMBL28087054 0.89 ALDH1A1 (0.88) ALDH1A1HPGDTDP1TRIM24ALDH5A1
Ethyl Vanillin SCHEMBL13516851 0.89 ALDH1A1 (0.88) ALDH1A1HPGDTDP1TRIM24ALDH5A1
Vanillin SCHEMBL8853913 0.88 ALDH1A1 (0.96) ALDH1A1HPGDTDP1TRIM24ALDH5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12324451-B2 Production of ethanol-free vanilla extracts SYMRISE AG (DE) 2025-06-10 US claimed
US-20230263202-A1 Production of Ethanol-free Vanilla Extracts SYMRISE AG (DE) 2023-08-24 US claimed
CN-113563166-B Synthesis method of vanillyl alcohol ether 珠海市柏瑞医药科技有限公司 2023-08-01 CN claimed
US-20210022381-A1 Production of Ethanol-free Vanilla Extracts SYMRISE AG (DE) 2021-01-28 US claimed
EP-3764813-A1 PRODUCTION OF ETHANOL-FREE VANILLA EXTRACTS Symrise AG (DE) 2021-01-20 EP claimed
WO-2019174723-A1 PRODUCTION OF ETHANOL-FREE VANILLA EXTRACTS SYMRISE AG (DE) 2019-09-19 WO claimed
EP-2861084-A1 NEUTRALLY BUOYANT INGESTIBLE COMPOSITIONS Adam, Georgius, Abidal (US) 2015-04-22 EP claimed
WO-2013187897-A1 NEUTRALLY BUOYANT INGESTIBLE COMPOSITIONS EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) 2013-12-19 WO claimed
US-12324451-B2 Production of ethanol-free vanilla extracts SYMRISE AG (DE) 2025-06-10 US disclosed
CN-118420442-B Method for preparing vanillin by reducing vanillin with silicon powder 天津市职业大学 2024-09-13 CN disclosed
CN-118420442-A Method for preparing vanillin by reducing vanillin with silicon powder 天津市职业大学 2024-08-02 CN disclosed
US-20230263202-A1 Production of Ethanol-free Vanilla Extracts SYMRISE AG (DE) 2023-08-24 US disclosed
CN-113563166-B Synthesis method of vanillyl alcohol ether 珠海市柏瑞医药科技有限公司 2023-08-01 CN disclosed
US-11672266-B2 Production of ethanol-free vanilla extracts SYMRISE AG (DE) 2023-06-13 US disclosed
WO-2008027533-A2 PERSONAL CARE COMPOSITIONS COMPRISING PEAR SEED EXTRACT THE PROCTER & GAMBLE COMPANY (US) 2008-03-06 WO disclosed
US-20070196296-A1 Personal care compositions PROCTER & GAMBLE COMPANY, THE 2007-08-23 US disclosed
US-20070185038-A1 Regulation of mammalian keratinous tissue using skin care actives THE PROCTER & GAMBLE COMPANY 2007-08-09 US disclosed
US-20070183993-A1 Personal care compositions PROCTER & GAMBLE COMPANY, THE 2007-08-09 US disclosed
WO-2007041548-A2 COMPOSITION FOR REGULATION OF MAMMALIAN KERATINOUS TISSUE THE PROCTER & GAMBLE COMPANY (US) 2007-04-12 WO disclosed
WO-2007001904-A2 PERSONAL CARE COMPOSITIONS COMPRISING ALPHA-GLUCANS AND/OR BETA-GLUCANS THE PROCTER & GAMBLE COMPANY (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070196296-A1 Personal care compositions CUTA, C5, F7 ALDH1A1 3550/4885HPGD 1444/4885TDP1 1957/4885
US-20070183993-A1 Personal care compositions PPARG, PPARA, PPARD ALDH1A1 2805/4885HPGD 662/4885TDP1 2918/4885
US-20070185038-A1 Regulation of mammalian keratinous tissue using skin care actives CUTA, KDM7A, KDM2A ALDH1A1 3455/4885HPGD 2220/4885TDP1 812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.